Clinical Trials Browser

Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT04644211 2026-01-08

Ruxolitinib in Thrombocythemia and Polycythemia Vera

Phase 2 Recruiting

60 enrolled

Myeloid

Polycythemia Vera, Thrombocythemia, Essential

NCT02577926 2025-06-10

Ruxo-BEAT

Phase 2 Active not recruiting

207 enrolled

Myeloid

Polycythemia Vera, Thrombocythemia, Essential

NCT01375140 2025-06-08

Ruxolitinib and Lenalidomide for Patients With Myelofibrosis

Phase 2 Completed

31 enrolled 8 charts

Myeloid

Polycythemia Vera, Primary Myelofibrosis

NCT04041050 2025-02-14

A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

Phase 1 Active not recruiting

85 enrolled

MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Neoplasms, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT05870475 2024-07-03

PV

Phase 2 Recruiting

94 enrolled

Myeloid

Polycythemia Vera

NCT04354727 2022-07-12

A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy

Phase 1/2 Withdrawn

Myeloid

Polycythemia Vera, Thrombocytosis, Primary Myelofibrosis

NCT01981850 2022-01-05

A Phase 2 Study of RO7490677 In Participants With Myelofibrosis

Phase 2 Completed

125 enrolled 38 charts

Myeloid

Fibrosis, Polycythemia Vera, Primary Myelofibrosis

NCT02038036 2021-07-20

RESPONSE-2

Phase 3 Completed

149 enrolled 19 charts

Myeloid

Bone Marrow Diseases, Hematologic Diseases, Myeloproliferative Disorders, Polycythemia Vera

NCT03669965 2020-07-31

KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera

Phase 2 Unknown

20 enrolled

Myeloid

Polycythemia Vera

NCT01787552 2020-04-15

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Phase 1/2 Completed

50 enrolled 23 charts

Myeloid

Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases, Hematologic Diseases, Hemorrhagic Disorders, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis, Primary Myelofibrosis

NCT02292446 2019-07-18

Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.

Phase 3 Completed

161 enrolled 14 charts

Myeloid

Hematologic Diseases, Myeloproliferative Disorders, Polycythemia Vera

NCT02267278 2019-06-12

Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)

Phase 2 Completed

25 enrolled 8 charts

Myeloid

Polycythemia Vera, Primary Myelofibrosis

NCT01243944 2019-03-06

Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

Phase 3 Completed

222 enrolled 21 charts

Myeloid

Polycythemia Vera

NCT00509899 2018-03-12

Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

Phase 1/2 Completed

154 enrolled 26 charts

Myeloid

Polycythemia Vera, Thrombocytosis, Primary Myelofibrosis

NCT01632904 2017-11-14

Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study

Phase 3 Completed

110 enrolled 11 charts

Myeloid

Polycythemia Vera

NCT01164163 2014-10-23

INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease

Phase 1 Completed

49 enrolled

LymphoidMyeloidOther hematologic neoplasm

Myeloproliferative Syndrome, Transient, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Clinical Trials

CINC424A2X01B Rollover Protocol

TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea

MITHRIDATE

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

Ruxolitinib in Thrombocythemia and Polycythemia Vera

Ruxo-BEAT

Ruxolitinib and Lenalidomide for Patients With Myelofibrosis

A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

PV

A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy

A Phase 2 Study of RO7490677 In Participants With Myelofibrosis

RESPONSE-2

KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.

Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)

Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study

INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease